Biocon, the bio pharmaceutical firm and its partner Quark Pharmaceuticals has received the Drug Controller General of India (DCGI)’s approval to proceed with clinical trials on human subjects for a new drug candidate, ‘QPI-1007’ aimed for ocular neuroprotection.
The Company has said in a statement that Biocon and Quark Pharmaceuticals also announced the randomisation of the first patient in India in the global Phase II/III study of the new drug candidate.
It further said that “Biocon and its partner, Quark Pharmaceuticals, have received approval from the Drug Controller General of India (DCGI) to proceed with the study, the first ever clinical trial of a siRNA (small interfering RNA) therapy in India.”
